Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use.
Dasatinib is a second-line tyrosine kinase inhibitor used in patients with imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia. Gastrointestinal bleeding may occur in up to 7% of patients using dasatinib, although, severe dasatinib-related acute colitis had rarely been reported. Here, we present the case of a 36-year-old female who progressed to acute myeloid leukemia after fourteen months of receiving imatinib for CML in the chronic phase and was treated with a dasatinib-containing chemotherapy regimen. On day 34 of treatment, the patient developed moderate abdominal pain and bloody diarrhea with mucous. Analyses of stool specimens were negative for parasites, Clostridium difficile, and other pathogenic bacteria. The cytomegalovirus pp65 antigen was negative in her blood leukocytes. A colonoscopy revealed acute colitis, and a mucosal biopsy showed nonspecific colitis. The patient was treated with broad-spectrum antibiotics, bowel rest and hydration, and dasatinib treatment was stopped. Her bloody diarrhea improved within 72 h. After confirming cytological remission, the patient received initial course of consolidation, and dasatinib treatment was reinstated. However, hemorrhagic colitis recurred. After discontinuing dasatinib, herhemorrhagic colitis drastically improved and did not recur following the administration of nilotinib. The characteristics of our patient suggest that dasatinib treatment can lead to hemorrhagic colitis, which typically resolves after discontinuation of the drug.
Zahra Kmira, Ben Sayed Nesrine, Ben Fredj Wafa, Ben Youssef Yosra, Zaier Monia, Khelif Abderrahim, Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Zahra
Z
Kmira
Ben Sayed
BS
Nesrine
Zaghouani
Z
Houneida
Ben Fredj
BF
Wafa
Slama
S
Aida
Ben Youssef
BY
Yosra
Zaier
Z
Monia
Badreddine
B
Sriha
Khelif
K
Abderrahim
Chronic myeloid leukemia; Colitis; Dasatinib; Philadelphia chromosome